Literature DB >> 22496400

Supplementation with galacto-oligosaccharides increases the percentage of NK cells and reduces colitis severity in Smad3-deficient mice.

Anita Gopalakrishnan1, Jonathan F Clinthorne, Elizabeth A Rondini, Sarah J McCaskey, Eric A Gurzell, Ingeborg M Langohr, Elizabeth M Gardner, Jenifer I Fenton.   

Abstract

The gut microbiota plays an essential role in intestinal immunity. Prebiotics, including galacto-oligosaccharides (GOS), are fermentable fibers that beneficially affect the host by stimulating the growth of specific microbial populations. We investigated the effect of GOS on colitis development and on immune variables in Smad3-deficient mice treated with the pathogen Helicobacter hepaticus. Mice were supplemented daily with 5000 mg GOS/kg body weight 2 wk prior to infection and 4 wk postinfection, a time period during which colitis severity peaks in this model. Mice (n = 4-8/treatment at each time) were killed preinfection (0 d) and at 3, 7, and 28 d postinfection to evaluate immune variables in the spleen and in mesenteric lymph nodes (MsLN) by flow cytometry. Colon and cecum samples were collected for histopathologic analysis. Fecal pellets (n = 8-9/treatment) were collected prior to infection to measure relative changes in Bifidobacterium ssp. and Lactobacillum ssp. by real-time PCR. GOS significantly reduced colitis severity in response to H. hepaticus (P < 0.0001). This was associated with a significant increase in the percentage of NK cells in the spleen (P < 0.001) and in MsLN (P < 0.001) at 3 d postinfection and a 1.5-fold increase in fecal Bifidobacterium ssp. (P = 0.003). GOS stimulated NK expression of CCR9, a chemokine receptor involved in lymphocyte trafficking to the gut preinfection (0 d) in the blood (P = 0.02), spleen (P = 0.033), and MsLN (P = 0.017). In addition, GOS stimulated colonic IL-15 production 3 d postinfection (P < 0.001). These data suggest that GOS reduces colitis by modulating the function and trafficking of NK cells and may provide a novel therapeutic strategy for individuals with inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496400     DOI: 10.3945/jn.111.154732

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  14 in total

Review 1.  Impact of dietary components on NK and Treg cell function for cancer prevention.

Authors:  Young S Kim; Thomas J Sayers; Nancy H Colburn; John A Milner; Howard A Young
Journal:  Mol Carcinog       Date:  2015-04-01       Impact factor: 4.784

2.  Galacto-oligosaccharides and Colorectal Cancer: Feeding our Intestinal Probiome.

Authors:  Jose M Bruno-Barcena; M Andrea Azcarate-Peril
Journal:  J Funct Foods       Date:  2015-01       Impact factor: 4.451

Review 3.  Microbiota-dependent and -independent effects of dietary fibre on human health.

Authors:  Yang Cai; Jelle Folkerts; Gert Folkerts; Marcus Maurer; Saskia Braber
Journal:  Br J Pharmacol       Date:  2019-12-12       Impact factor: 8.739

4.  Dietary Human Milk Oligosaccharides but Not Prebiotic Oligosaccharides Increase Circulating Natural Killer Cell and Mesenteric Lymph Node Memory T Cell Populations in Noninfected and Rotavirus-Infected Neonatal Piglets.

Authors:  Sarah S Comstock; Min Li; Mei Wang; Marcia H Monaco; Theresa B Kuhlenschmidt; Mark S Kuhlenschmidt; Sharon M Donovan
Journal:  J Nutr       Date:  2017-05-10       Impact factor: 4.798

Review 5.  Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.

Authors:  Taekil Eom; Yong Sung Kim; Chang Hwan Choi; Michael J Sadowsky; Tatsuya Unno
Journal:  J Microbiol       Date:  2018-02-28       Impact factor: 3.422

Review 6.  Prebiotics in infant formula.

Authors:  Yvan Vandenplas; Elisabeth De Greef; Gigi Veereman
Journal:  Gut Microbes       Date:  2014

7.  High purity galacto-oligosaccharides enhance specific Bifidobacterium species and their metabolic activity in the mouse gut microbiome.

Authors:  A Monteagudo-Mera; J C Arthur; C Jobin; T Keku; J M Bruno-Barcena; M A Azcarate-Peril
Journal:  Benef Microbes       Date:  2016-02-03       Impact factor: 4.205

Review 8.  Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer.

Authors:  Maya Raman; Padma Ambalam; Kanthi Kiran Kondepudi; Sheetal Pithva; Charmy Kothari; Arti T Patel; Ravi Kiran Purama; J M Dave; B R M Vyas
Journal:  Gut Microbes       Date:  2013-03-19

9.  Effects of orally administered galacto-oligosaccharides on immunological parameters in foals: a pilot study.

Authors:  Johannes Cornelis Vendrig; Luc Edgar Coffeng; Johanna Fink-Gremmels
Journal:  BMC Vet Res       Date:  2014-11-19       Impact factor: 2.741

10.  In vitro evaluation of defined oligosaccharide fractions in an equine model of inflammation.

Authors:  Johannes Cornelis Vendrig; Luc Edgar Coffeng; Johanna Fink-Gremmels
Journal:  BMC Vet Res       Date:  2013-07-22       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.